drugset / Trial / NCT01540760
A Study of MCAF5352A in Healthy Volunteers
RandomizedParallel-groupDouble-blind
Summary
This single-center, randomized, placebo-controlled, double-blind, multiple ascending dose study will evaluate the safety, pharmacokinetics and immunogenicity of MCAF5352A in healthy volunteers. Subjects will be randomized to receive either MCAF5352A or placebo on Days 1, 15 and 29.
Timeline
- Start
- 2012-03
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AFASEVIKUMAB | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.